Fernando, Fiona
Andres, Maria Sol
Claudiani, Simone
Kermani, Nazanin Zounemat
Ceccarelli, Giulia
Innes, Andrew J.
Khan, Afzal
Rosen, Stuart D.
Apperley, Jane F.
Lyon, Alexander R.
Milojkovic, Dragana
Article History
Received: 13 May 2024
Accepted: 1 July 2024
First Online: 15 July 2024
Declarations
:
: ARL has received speaker, advisory board or consultancy fees and/or research grants from Janssens-Cilag Ltd, Astellas Pharma, Pfizer, Novartis, Servier, Astra Zeneca, Bristol Myers Squibb, GSK, Amgen, Takeda, Roche, Clinigen Group, Eli Lily, Eisai Ltd, Ferring Pharmaceuticals, Boehringer Ingelheim, Akcea Therapeutics, Myocardial Solutions, iOWNA Health and Heartfelt Technologies Ltd. MSA is funded by the Royal Brompton Hospital Charity. ARL is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology and the Royal Brompton Cardio-Oncology Centre of Excellence is supported by the The Big Heart Foundation. The remaining authors have nothing to disclose.